Grandfield & Dodd, LLC Ionis Pharmaceuticals Inc Transaction History

Grandfield & Dodd, LLC

$1.61 Billion
Q2 2025

A detailed history of Grandfield & Dodd, LLC transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Grandfield & Dodd, LLC holds 37,230 shares of IONS stock, worth $2.72 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

37,230

Previous 37,761 1.41%

Holding current value

$2.72 Million

Previous $1.14 Million 29.06%

% of portfolio

0.09%

Previous 0.07%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 08, 2025	SELL	$25.51 - $40.0 $13,545 - $21,240	-531 Reduced 1.41%	37,230 $1.47 Million
Q1 2025 May 02, 2025	BUY	$30.17 - $34.97 $56,538 - $65,533	1,874 Added 5.22%	37,761 $1.14 Million
Q4 2024 Feb 06, 2025	BUY	$33.73 - $40.36 $36,226 - $43,346	1,074 Added 3.09%	35,887 $1.25 Million
Q3 2024 Nov 08, 2024	BUY	$40.06 - $51.86 $30,445 - $39,413	760 Added 2.23%	34,813 $1.39 Million
Q2 2024 Aug 09, 2024	BUY	$36.45 - $47.7 $10,169 - $13,308	279 Added 0.83%	34,053 $1.62 Million
Q1 2024 May 03, 2024	BUY	$42.03 - $53.55 $28,160 - $35,878	670 Added 2.02%	33,774 $1.46 Million
Q4 2023 Jan 31, 2024	BUY	$43.39 - $51.63 $10,500 - $12,494	242 Added 0.74%	33,104 $1.67 Million
Q3 2023 Oct 25, 2023	BUY	$38.5 - $47.13 $7,045 - $8,624	183 Added 0.56%	32,862 $1.49 Million
Q2 2023 Aug 07, 2023	BUY	$34.73 - $43.33 $13,718 - $17,115	395 Added 1.22%	32,679 $1.34 Million
Q1 2023 Apr 28, 2023	BUY	$33.58 - $41.2 $27,199 - $33,372	810 Added 2.57%	32,284 $1.15 Million
Q4 2022 Jan 20, 2023	BUY	$37.12 - $46.52 $89,199 - $111,787	2,403 Added 8.27%	31,474 $0
Q3 2022 Nov 03, 2022	BUY	$36.54 - $48.66 $29,049 - $38,684	795 Added 2.81%	29,071 $1.29 Million
Q2 2022 Aug 01, 2022	BUY	$31.71 - $43.0 $8,720 - $11,825	275 Added 0.98%	28,276 $1.05 Million
Q1 2022 Apr 19, 2022	BUY	$29.88 - $37.04 $36,752 - $45,559	1,230 Added 4.59%	28,001 $1.04 Million
Q4 2021 Feb 08, 2022	BUY	$25.61 - $35.1 $130,098 - $178,308	5,080 Added 23.42%	26,771 $810,000
Q3 2021 Oct 28, 2021	BUY	$33.54 - $40.55 $21,398 - $25,870	638 Added 3.03%	21,691 $730,000
Q2 2021 Jul 28, 2021	BUY	$34.54 - $47.25 $24,178 - $33,075	700 Added 3.44%	21,053 $840,000
Q1 2021 Apr 22, 2021	BUY	$42.51 - $63.78 $30,224 - $45,347	711 Added 3.62%	20,353 $920,000
Q4 2020 Jan 29, 2021	BUY	$45.3 - $60.27 $27,406 - $36,463	605 Added 3.18%	19,642 $1.11 Million
Q3 2020 Nov 03, 2020	BUY	$47.45 - $62.95 $15,943 - $21,151	336 Added 1.8%	19,037 $900,000
Q2 2020 Jul 24, 2020	BUY	$46.85 - $61.05 $63,950 - $83,333	1,365 Added 7.87%	18,701 $1.1 Million
Q1 2020 May 14, 2020	BUY	$41.6 - $63.4 $27,456 - $41,844	660 Added 3.96%	17,336 $820,000
Q4 2019 Feb 07, 2020	BUY	$53.85 - $65.27 $46,041 - $55,805	855 Added 5.4%	16,676 $1.01 Million
Q3 2019 Oct 30, 2019	BUY	$59.06 - $72.15 $69,100 - $84,415	1,170 Added 7.99%	15,821 $948,000
Q2 2019 Jul 29, 2019	BUY	$62.09 - $86.14 $50,168 - $69,601	808 Added 5.84%	14,651 $942,000
Q1 2019 Apr 26, 2019	BUY	$52.92 - $81.17 $5,239 - $8,035	99 Added 0.72%	13,843 $1.12 Million
Q4 2018 Feb 12, 2019	BUY	$43.37 - $59.54 $7,156 - $9,824	165 Added 1.22%	13,744 $743,000
Q3 2018 Nov 02, 2018	BUY	$42.88 - $53.7 $4,716 - $5,907	110 Added 0.82%	13,579 $700,000
Q2 2018 Jul 27, 2018	BUY	$40.53 - $50.7 $3,242 - $4,056	80 Added 0.6%	13,469 $561,000
Q1 2018 May 04, 2018	SELL	$44.08 - $55.05 $12,342 - $15,414	-280 Reduced 2.05%	13,389 $590,000
Q4 2017 Feb 06, 2018	BUY	$50.3 - $64.39 $14,587 - $18,673	290 Added 2.17%	13,669 $688,000
Q3 2017 Nov 03, 2017	BUY	$45.56 - $59.57 $609,547 - $796,987	13,379	13,379 $678,000

Others Institutions Holding IONS

# of Institutions

415

Shares Held

149M

Call Options Held

1.72M

Put Options Held

722K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $10.4B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Grandfield & Dodd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Grandfield & Dodd, LLC with notifications on news.

Account

Grandfield & Dodd, LLC Ionis Pharmaceuticals Inc Transaction History